Abdul Moiz1, Tariq Javed2, Jorge Garces3, Catherine Staffeld-Coit3, Paisit Paueksakon4. 1. Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA ; Multi-Organ Transplant Institute, Ochsner Clinic Foundation, New Orleans, LA ; The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA. 2. Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA. 3. Department of Nephrology, Ochsner Clinic Foundation, New Orleans, LA ; Multi-Organ Transplant Institute, Ochsner Clinic Foundation, New Orleans, LA. 4. Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN.
Abstract
BACKGROUND: Light chain deposition disease (LCDD) recurs frequently after renal transplantation with variable presentation. CASE REPORT: We report the case of a 67-year-old Caucasian female with recurrence of LCDD after living-donor kidney transplantation. Bone marrow biopsy revealed kappa light chain-restricted population of plasma cells, and the patient met the criteria for multiple myeloma. Her renal function progressively worsened and she became dialysis dependent. She received 1 cycle of bortezomib along with intravenous dexamethasone. She was able to discontinue dialysis within 2 months, and at 1 year follow-up her renal function was stable. CONCLUSION: Bortezomib has a role in the treatment of recurrent LCDD and multiple myeloma in kidney transplant patients. As opposed to traditional regimens, a short course may be beneficial.
BACKGROUND: Light chain deposition disease (LCDD) recurs frequently after renal transplantation with variable presentation. CASE REPORT: We report the case of a 67-year-old Caucasian female with recurrence of LCDD after living-donor kidney transplantation. Bone marrow biopsy revealed kappa light chain-restricted population of plasma cells, and the patient met the criteria for multiple myeloma. Her renal function progressively worsened and she became dialysis dependent. She received 1 cycle of bortezomib along with intravenous dexamethasone. She was able to discontinue dialysis within 2 months, and at 1 year follow-up her renal function was stable. CONCLUSION:Bortezomib has a role in the treatment of recurrent LCDD and multiple myeloma in kidney transplantpatients. As opposed to traditional regimens, a short course may be beneficial.
Authors: Samih H Nasr; Anthony M Valeri; Lynn D Cornell; Mary E Fidler; Sanjeev Sethi; Vivette D D'Agati; Nelson Leung Journal: Clin J Am Soc Nephrol Date: 2011-12-08 Impact factor: 8.237
Authors: J F San-Miguel; P G Richardson; P Sonneveld; M W Schuster; D Irwin; E A Stadtmauer; T Facon; J-L Harousseau; D Ben-Yehuda; S Lonial; H Goldschmidt; D Reece; J Bladé; M Boccadoro; J D Cavenagh; R Neuwirth; A L Boral; D-L Esseltine; K C Anderson Journal: Leukemia Date: 2008-01-17 Impact factor: 11.528
Authors: Elizabeth C Lorenz; Morie A Gertz; Fernando C Fervenza; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Dennis A Gastineau; Nelson Leung Journal: Nephrol Dial Transplant Date: 2008-01-04 Impact factor: 5.992
Authors: Nelson Leung; Donna J Lager; Morie A Gertz; Kirk Wilson; Sharan Kanakiriya; Fernando C Fervenza Journal: Am J Kidney Dis Date: 2004-01 Impact factor: 8.860